Danaher: Is the Science Giant a Buy?

Is Danaher a buy despite recent struggles? We dive into the science and tech giant's $147B empire, dissecting its underperforming stock, strong Q2 earnings, and promising future in bioprocessing. Find out why analysts predict an 18% upside, even as competitors like IDEXX surge ahead. Hosted on Acast. See acast.com/privacy for more information.